Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cartherics celebrates PhD student’s success
By Karen Loudon / February 6, 2023
Cartherics is delighted to announce that Saleh Almasabi has successfully completed his PhD Candidature. Saleh’s research thesis, ‘The role of...
Read More
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
By Karen Loudon / January 20, 2023
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and...
Read More
Cartherics granted first patent in China for multiple development candidates
By Karen Loudon / January 9, 2023
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment...
Read More
